Pfizer Inc. (NYSE:PFE) Shares Purchased by Lake Street Advisors Group LLC

Lake Street Advisors Group LLC grew its stake in shares of Pfizer Inc. (NYSE:PFE) by 17.1% during the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 27,135 shares of the biopharmaceutical company’s stock after purchasing an additional 3,963 shares during the quarter. Lake Street Advisors Group LLC’s holdings in Pfizer were worth $753,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also modified their holdings of the stock. Creekmur Asset Management LLC acquired a new stake in shares of Pfizer during the fourth quarter worth about $32,000. Trivant Custom Portfolio Group LLC lifted its stake in Pfizer by 100.0% in the first quarter. Trivant Custom Portfolio Group LLC now owns 1,200 shares of the biopharmaceutical company’s stock valued at $33,000 after buying an additional 600 shares during the last quarter. Tennessee Valley Asset Management Partners acquired a new stake in shares of Pfizer in the fourth quarter valued at approximately $36,000. DiNuzzo Private Wealth Inc. purchased a new position in shares of Pfizer during the fourth quarter worth approximately $37,000. Finally, ESL Trust Services LLC acquired a new position in shares of Pfizer in the 1st quarter valued at $37,000. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently weighed in on the stock. Barclays increased their target price on shares of Pfizer from $28.00 to $30.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 10th. BMO Capital Markets reissued an “outperform” rating and issued a $36.00 target price (up previously from $33.00) on shares of Pfizer in a report on Thursday, May 2nd. Morgan Stanley upped their price target on Pfizer from $28.00 to $29.00 and gave the stock an “equal weight” rating in a research note on Thursday, May 2nd. Finally, Cantor Fitzgerald reiterated an “overweight” rating and issued a $45.00 price objective on shares of Pfizer in a research report on Wednesday, July 10th. Nine equities research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus price target of $34.50.

Pfizer Trading Up 1.5 %

Shares of Pfizer stock traded up $0.45 during trading hours on Thursday, reaching $30.43. 16,676,816 shares of the company’s stock were exchanged, compared to its average volume of 39,564,738. The firm has a market capitalization of $172.43 billion, a price-to-earnings ratio of -507.25, a price-to-earnings-growth ratio of 1.15 and a beta of 0.69. The company has a current ratio of 1.05, a quick ratio of 0.78 and a debt-to-equity ratio of 0.66. Pfizer Inc. has a 52-week low of $25.20 and a 52-week high of $37.35. The company has a fifty day moving average of $28.47 and a 200-day moving average of $27.75.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported $0.82 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.56 by $0.26. Pfizer had a positive return on equity of 8.64% and a negative net margin of 0.56%. The firm had revenue of $14.88 billion for the quarter, compared to analyst estimates of $13.87 billion. During the same period last year, the company earned $1.23 EPS. The firm’s quarterly revenue was down 19.5% on a year-over-year basis. Sell-side analysts forecast that Pfizer Inc. will post 2.39 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th will be given a dividend of $0.42 per share. The ex-dividend date is Friday, July 26th. This represents a $1.68 dividend on an annualized basis and a dividend yield of 5.52%. Pfizer’s payout ratio is currently -2,799.53%.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.